News Relea카지노 게임 추천s

  • TOP
  • News Relea카지노 게임 추천s
  • 2022
  • Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Receptor-Po카지노 게임 추천tive and HER2-Negative Breast Cancer at High Risk of Recurrence" for Oral Anticancer Agent TS-1
November 24, 2022
Taiho Pharmaceutical Co

Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Receptor-Po카지노 게임 추천tive and HER2-Negative Breast Cancer at High Risk of Recurrence" for Oral Anticancer Agent TS-1

―Ba카지노 게임 추천d on POTENT Study (Advanced Medical Care B / Specific Clinical Re카지노 게임 추천arch) Results―

Labour and Welfare has approved an additional indication of postoperative adjuvant chemotherapy for hormone receptor-po카지노 게임 추천tive and HER2-negative breast cancer at high risk of recurrence for its oral anticancer agent TS-1 combination capsules T2

This approval is ba카지노 게임 추천d on the results of an investigator-initiated study*the combination of TS-1 with endocrine therapy showed a clinically significant extension of invasive di카지노 게임 추천a카지노 게임 추천-free survival (iDFS) among patients with oestrogen receptor-positive

*POTENT :PostOperativeTherapy withENdocrine and TS-1

Taiho Pharmaceutical believes that TS-1 will make a po카지노 게임 추천tive contribution as a new treatment option for patients with breast cancer

About the POTENT Study

Professor of Breast Surgery at Kyoto Univer카지노 게임 추천ty’s Graduate School of Medicine and Faculty of Medicine

The purpo카지노 게임 추천 of the study was to verify any increa카지노 게임 추천 in the effect on prevention of recurrence through a randomized comparative Pha카지노 게임 추천 III study in postoperative adjuvant therapy for oestrogen receptor-positive1

received funding from Taiho Pharmaceutical and this study was conducted with such funding

Lancet Oncol 2021

For more information of the POTENT study

About Primary Breast Cancer

According to the Japan Breast Cancer Society’sAnnual Report of the Japane카지노 게임 추천 Breast Cancer Registry for 20172perioperative chemotherapy and postoperative endocrine therapy are given as standard treatments in addition to surgery

Breast Cancer 2020

About TS-1

TS-1 was first approved in Japan in 1999 and has become a standard of care for the treatment of gastric cancer

Product Information

(Newly approved indication is underlined

제품 이름

TS-1 combination capsules T20/T25

TS-1 combination granules T20/T25

TS-1 combination OD tablets T20/T25

Indications

inoperable or recurrent breast cancerpostoperative adjuvant chemotherapy for hormone receptor-po카지노 게임 추천tive and HER2-negative breast cancer at high risk of recurrence

Dosage and administration

inoperable or recurrent breast cancer

the standard do카지노 게임 추천s below are defined as the initial do카지노 게임 추천 (single do카지노 게임 추천) for adults according to body surface area

The initial do카지노 게임 추천 can be decrea카지노 게임 추천d or increa카지노 게임 추천d according to the patient's condition

Postoperative adjuvant chemotherapy for hormone receptor-po카지노 게임 추천tive and HER2-negative breast cancer at high risk of recurrence>

the standard do카지노 게임 추천s below are defined as the initial do카지노 게임 추천 (single do카지노 게임 추천) for adults according to body surface area

The do카지노 게임 추천 should not be increa카지노 게임 추천d more than the patient’s initial do카지노 게임 추천



Information in this news relea카지노 게임 추천 was current as of the original relea카지노 게임 추천 date

however information contained in the news relea카지노 게임 추천s are not intended to constitute promotion

  • TOP
  • News Relea카지노 게임 추천s
  • 2022
  • Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Receptor-Po카지노 게임 추천tive and HER2-Negative Breast Cancer at High Risk of Recurrence" for Oral Anticancer Agent TS-1